Resistant Hypertension

Journal of the American Board of Family Medicine

Volumn 25, Issue 4, 2012, Pages 487-495

  Viera, Anthony J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Hypertension; Review

Indexed keywords

AMFEBUTAMONE; AMILORIDE; AMPHETAMINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; COCAINE; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PSEUDOEPHEDRINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; UNINDEXED DRUG; VENLAFAXINE;

ADRENAL CORTEX ADENOMA; ADRENAL HYPERPLASIA; ALCOHOL CONSUMPTION; ALCOHOLISM; AMBULATORY MONITORING; ANTIHYPERTENSIVE THERAPY; AORTA COARCTATION; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CATHETER; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CUSHING DISEASE; DIET RESTRICTION; DIET SUPPLEMENTATION; DIURETIC THERAPY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EPHEDRA; EPHEDRA SINICA; GINSENG; GLOMERULUS FILTRATION RATE; GLYCYRRHIZA; HERB; HOME MONITORING; HUMAN; HYPERALDOSTERONISM; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY ANGIOGRAPHY; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; KIDNEY FUNCTION; LOW DRUG DOSE; MEDICAL SPECIALIST; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT REFERRAL; PHEOCHROMOCYTOMA; PLASMA RENIN ACTIVITY; POLYCYTHEMIA; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; RADIOFREQUENCY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; REVIEW; SELF MONITORING; SIDE EFFECT; SLEEP APNEA SYNDROME; SODIUM RESTRICTION; SOUR ORANGE; TREATMENT INDICATION; WHITE COAT HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; COMORBIDITY; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; PATIENT COMPLIANCE; RENAL ARTERY OBSTRUCTION; TREATMENT FAILURE; WHITE COAT HYPERTENSION;

EID: 84863694445     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2012.04.110275     Document Type: Review

References (52)

1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19.
2. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011;57:1076-80.
3. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011;57:898-902.
4. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81. (Pubitemid 23154254)
5. Viera AJ, Jamieson B, Dealleaume L. Clinical inquiries. How effective are hypertension self-care interventions? J Fam Pract 2007;56:229-31. (Pubitemid 46453734)
6. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-9. (Pubitemid 47176510)
7. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: Blood pressure measurement in humans. A statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697-716. (Pubitemid 40216499)
8. Reeves RA. The rational clinical examination. Does this patient have hypertension? How to measure blood pressure. JAMA 1995;273:1211-8.
9. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens 2001;14:1263-9. (Pubitemid 33151484)
10. Myers MG, Valdivieso M, Kiss A. Use of automated office blood pressure measurement to reduce the white coat response. J Hypertens 2009;27:280-6.
11. Pickering TG, White WB. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens 2008;2:119-24. (Pubitemid 351699668)
12. Gerin W, Schwartz AR, Schwartz JE, et al. Limitations of current validation protocols for home blood pressure monitors for individual patients. Blood Press Monit 2002;7:313-8. (Pubitemid 36140458)
13. Verberk WJ, Kroon AA, Kessels AG, et al. The optimal scheme of self blood pressure measurement as determined from ambulatory blood pressure recordings. J Hypertens 2006;24(8):1541-8. (Pubitemid 44162455)
14. Egan BM, Zhao Y, Axon N, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011;124:1046-58.
15. Beckett NS, Peters R, Fletcher AE, et al HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358(18):1887-98. (Pubitemid 351620109)
16. Fagard RH, Staessen JA, Thijs L, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med 2007;167:1884-91. (Pubitemid 47481484)
17. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003;42:878-84. (Pubitemid 37413724)
18. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. (Pubitemid 37430158)
19. Calhoun DA, Nishizaka MK, Zaman MA, Thakar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40:892-6. (Pubitemid 35434912)
20. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003;42:161-5. (Pubitemid 36944590)
21. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosteronerenin ratio. Am J Kidney Dis 2001;37:699-705. (Pubitemid 32268029)
22. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008;371:1921-6. (Pubitemid 351778191)
23. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266-81.
24. Mulgrew AT, Fox N, Ayas NT, Ryan CF. Diagnosis and initial management of obstructive sleep apnea without polysomnography. Ann Intern Med 2007;146:157-66. (Pubitemid 351650628)
25. Skomro RP, Gjevre J, Reid J, et al. Outcomes of home-based diagnosis and treatment of obstructive sleep apnea. Chest 2010;138(2):257-63.
26. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001;19:2271-7. (Pubitemid 33135251)
27. Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003;107(1):68-73. (Pubitemid 36070935)
28. Eklöf H, Ahlström H, Magnusson A, et al. A prospective comparison of duplex ultrasonography, captopril renography, MRA, and CTA in assessing renal artery stenosis. Acta Radiol 2006;47:764-74. (Pubitemid 44521233)
29. Astral Investigators, Wheatley K, Ives N, Gray R, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009;361:1953-62.
30. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium restriction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009;54:444-6.
31. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
32. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3255-64.
33. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-8. (Pubitemid 43740274)
34. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9. (Pubitemid 38031903)
35. Ernst ME, Neaton JD, Grimm RH, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the Multiple Risk Factor Intervention Trial. Hypertension 2011;58:1001-7.
36. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011;57:689-94.
37. Grogan JR, Kochar MS. Alcohol and hypertension. Arch Fam Med 1994;3:150-4.
38. Viera AJ, Kshirsagar AV, Hinderliter AL. Lifestyle modification advice for lowering or controlling high blood pressure: who's getting it? J Clin Hypertens (Greenwich) 2007;9:850-8.
39. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10. (Pubitemid 32064838)
40. Law MR, Wald NJ, Morris JR, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ 2003;326:1427-81.
41. Mann JF, Schmieder RE, McQueen M, et al; for the ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53.
42. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-45. (Pubitemid 351664214)
43. Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, doubleblind, placebo-controlled trial. Hypertension 2011;57:1069-75.
44. Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005;46:481-7. (Pubitemid 41376826)
45. Saseen JJ, Carter BL, Brown TE, Elliott WJ, Black HR. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension 1996;28(1):109-14. (Pubitemid 26231098)
46. Bakris G. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med 2001;161:2661-7. (Pubitemid 33134841)
47. Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg 2006;44:1213-8.
48. Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010;56:1254-8.
49. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension. Results from the doubleblind, randomized, placebo-controlled Rheos pivotal trial. J Am Coll Cardiol 2011;58:765-73.
50. Krum H, Schlaich M, Whitbourn R, et al. Catheterbased renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-81.
51. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-9.
52. Viera AJ, Hinderliter AL. Evaluation and management of the patient with difficult-to-control or resistant hypertension. Am Fam Physician 2009;79:863-9.